Hepatology Research

Papers
(The H4-Index of Hepatology Research is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach122
Evidence‐based clinical practice guidelines for liver cirrhosis 2020107
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 202077
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)74
MAFLD: Renovation of clinical practice and disease awareness of fatty liver62
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)48
Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)42
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice41
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan41
Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study40
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease36
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy33
Hepatocellular carcinoma after Fontan surgery: A systematic review33
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma32
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study32
Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis31
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis31
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis26
Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen26
Association of coagulopathy with liver dysfunction in patients with COVID‐1926
Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR‐3619‐5p/SOX926
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma24
Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases24
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multic23
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma23
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matche23
Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study23
Serum matrix metalloproteinase‐7 in biliary atresia: A Japanese multicenter study23
0.02921199798584